Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERN/LRPT/simvastatin fixed-dose combination equivalence study in dyslipidemia
NL-OMON36032Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of laropiprant and simvastatin, sponsored by Merck & Co. Started Oct 2011; status: active, not recruiting.
02
Drugs
laropiprantsimvastatin
Beyond the preview
Go deeper on NL-OMON36032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36032.